Bilaal.Raja
Company record

DMRA  Damora Therapeutics, Inc.

Trailing twelve months to 2026-06-30, as filed 2026-08-10 and not restated since.
Healthcare

Scale

Market cap
$1.3bn
Revenue TTM
$8m
Net income TTM
$-263m
Free cash flow
—
Composite score
—
Sector rank
#1832

Valuation

P / E
—
EV / EBITDA
—
EV / sales
89.9
FCF yield
—
Yield vs 10-yr
-25.89pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 5.28% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-3,216.2%
EBITDA margin
-3,311.7%
ROE
-50.9%
ROIC
—
Revenue growth
1,541.0%

Insider activity, last 90 days

Net open-market
$0.25m
Buyers
1
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Liquidity and management plans Since inception, the Company has devoted substantially all its efforts to business planning, research and development, recruiting management and technical staff and raising capital, and has financed its operations primarily through the issuance of preferred shares, debt financings, the Company’s initial public offering and sales of Common Stock. Product candidates in later stages of clinical development generally incur higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. …Damora Therapeutics, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-10

Read the full passage →